Brain cancer hope: new drug cocktail targets rare lymphoma
NCT ID NCT04446962
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 24 times
Summary
This study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning patients to one of the two drug combinations. The goal is to see if more patients achieve complete remission after four cycles of treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CH Colmar
Colmar, France
-
CH côte Basque
Bayonne, 64100, France
-
CHRU Lille
Lille, 69000, France
-
CHU Amiens
Amiens, France
-
CHU Angers
Angers, France
-
CHU Besançon
Besançon, France
-
CHU Caen
Caen, France
-
CHU Clermont-Ferrand
Clermont-Ferrand, France
-
CHU Créteil
Créteil, France
-
CHU Dijon
Dijon, France
-
CHU Grenoble
Grenoble, France
-
CHU La Timone Marseille
Marseille, France
-
CHU Limoges
Limoges, France
-
CHU Lyon
Lyon, France
-
CHU Nancy
Nancy, France
-
CHU Nantes
Nantes, France
-
CHU Nîmes - Carémeau
Nîmes, 30029, France
-
CHU Pitié-Salpêtrière
Paris, 75013, France
-
CHU Poitiers
Poitiers, France
-
CHU Rennes
Rennes, 35000, France
-
CHU Strasbourg-Hôpital Hautepierre
Strasbourg, 67098, France
-
CHU Tours
Tours, France
-
Centre Henri Becquerel
Rouen, 76000, France
-
Centre Lacassagne
Nice, France
-
Hôpital Cochin
Paris, 75006, France
-
IUCT -Oncopole
Toulouse, France
-
Institut Bergonié
Bordeaux, France
-
Institut Curie
Paris, 75005, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenalidomide (Revlimid) and ibrutinib (Imbruvica)
What this could lead to
If successful, this could improve the chance of complete remission for people with a rare brain lymphoma, potentially leading to a more effective first treatment.
What could go wrong
This is an early-phase trial (phase 1b/2) with a small number of participants, so results may not apply broadly. The drugs can cause serious side effects like infections or blood clots.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.